Thomas Cerny
Anti-nicotine vaccination: where are we?
Cerny T. Anti-nicotine vaccination: where are we?. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2005; 166:167-75.
Jan 1, 2005Anti-nicotine vaccination: where are we?
Jan 1, 2005Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2005; 166:167-75
Cerny Thomas
Hypertriglyceridemia as a possible risk factor for prostate cancer
Würmli L, Jörger M, Henz S, Schmid H, Riesen W, Thomas G, Krek W, Cerny T, Gillessen Sommer S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005; 8:316-320.
Jan 1, 2005Hypertriglyceridemia as a possible risk factor for prostate cancer
Jan 1, 2005Prostate Cancer Prostatic Dis 2005; 8:316-320
Würmli LIneta, Jörger Markus, Henz Samuel, Schmid Hans-Peter, Riesen Walter F, Thomas G, Krek W, Cerny Thomas, Gillessen Sommer Silke
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
Jun 15, 2004Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Jun 15, 2004Blood 2004; 103:4416-23
Ghielmini Michele, Vorobiof Daniel, Bargetzi Mario, Lohri Andreas, Helg Claudine, Kovacsovics Tibor, Stupp Roger, Zucca Emanuele, Hess Urs, Peccatori Fedro, Martinelli Giovanni, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Hummerjohann Jörg, Pichert Gabriella, Cogliatti Sergio B, Schmitz Shu-Fang Hsu, Cerny Thomas
[Mabthera for treatment of malignant lymphoma]
Cerny T, Hitz F, Gillessen Sommer S. [Mabthera for treatment of malignant lymphoma]. Therapeutische Umschau. Revue thérapeutique 2004; 61:379-83.
Jun 1, 2004[Mabthera for treatment of malignant lymphoma]
Jun 1, 2004Therapeutische Umschau. Revue thérapeutique 2004; 61:379-83
Cerny Thomas, Hitz Felicitas, Gillessen Sommer Silke
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny T, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillessen Sommer S, Dietrich D, Bernhard J, Schmid H. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. British journal of cancer 2004; 90:1312-7.
Apr 5, 2004Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial
Apr 5, 2004British journal of cancer 2004; 90:1312-7
Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny Thomas, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillessen Sommer Silke, Dietrich D, Bernhard J, Schmid H-P
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
Bertoni F, Cotter F, Cavalli F, Zucca E, Auer R, Jones C, Baldini L, Ponzoni M, Bertolini F, Pichert G, Fey M, Cerny T, Ghielmini M, Schmitz S, Cogliatti S, Conconi A, Swiss Group for Clinical Cancer Research. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. British journal of haematology 2004; 124:289-98.
Feb 1, 2004Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
Feb 1, 2004British journal of haematology 2004; 124:289-98
Bertoni Francesco, Cotter Finbarr E, Cavalli Franco, Zucca Emanuele, Auer Rebecca, Jones Chris, Baldini Luca, Ponzoni Maurilio, Bertolini Francesco, Pichert Gabriella, Fey Martin, Cerny Thomas, Ghielmini Michele, Schmitz Shu-Fang Hsu, Cogliatti Sergio B, Conconi Annarita, Swiss Group for Clinical Cancer Research
Acute pericarditis and pleural effusion complicating cytarabine chemotherapy
Gähler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie 2003; 26:348-50.
Aug 1, 2003Acute pericarditis and pleural effusion complicating cytarabine chemotherapy
Aug 1, 2003Onkologie 2003; 26:348-50
Gähler A, Hitz F, Hess U, Cerny Thomas
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9.
May 1, 2003Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
May 1, 2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9
Betticher Daniel C, Stahel Rolf, Weder Walter, Stupp Roger, Egli Fritz, Furrer Markus, Honegger Hanspeter, Wernli Martin, Cerny Thomas, Spiliopoulos Anastase, Roth Arnaud D, Hsu Schmitz Shu-Fang, Tötsch Martin, Hansen Eva, Joss Christine, von Briel Christian, Schmid Ralph A, Pless Miklos, Habicht James, Ris Hans-Beat
Thalidomide: from tragedy to promise
von Moos R, Stolz R, Cerny T, Gillessen Sommer S. Thalidomide: from tragedy to promise. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:77-87.
Feb 8, 2003Thalidomide: from tragedy to promise
Feb 8, 2003Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2003; 133:77-87
von Moos Roger, Stolz Rahel, Cerny Thomas, Gillessen Sommer Silke
[Intravitreal chemotherapy for intraocular lymphoma]
Helbig H, Cerny T, de Smet M. [Intravitreal chemotherapy for intraocular lymphoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2003; 100:145-9.
Feb 1, 2003[Intravitreal chemotherapy for intraocular lymphoma]
Feb 1, 2003Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2003; 100:145-9
Helbig H, Cerny Thomas, de Smet M D
HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study
D'Addario G, Ketterer N, Fey M, Cavalli F, Lohri A, Egli F, Stahel R, Maibach R, Torhorst J, Dieterle A, Cerny T. HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. Leukemia & lymphoma 2003; 44:133-8.
Jan 1, 2003HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study
Jan 1, 2003Leukemia & lymphoma 2003; 44:133-8
D'Addario Giannicola, Ketterer Nicolas, Fey Martin, Cavalli Franco, Lohri Andreas, Egli Fritz, Stahel Rolf, Maibach Rudolf, Torhorst Joachim, Dieterle Alexander, Cerny Thomas
Postradiation high-grade myofibroblastic sarcoma of the prostate -- a rare entity of prostatic tumors -- responding to liposomal Doxorubicin
Jörger M, Öhlschlegel C, Cerny T, Gillessen Sommer S. Postradiation high-grade myofibroblastic sarcoma of the prostate -- a rare entity of prostatic tumors -- responding to liposomal Doxorubicin. Onkologie 2002; 25:558-61.
Dec 1, 2002Postradiation high-grade myofibroblastic sarcoma of the prostate -- a rare entity of prostatic tumors -- responding to liposomal Doxorubicin
Dec 1, 2002Onkologie 2002; 25:558-61
Jörger Markus, Öhlschlegel Christian, Cerny Thomas, Gillessen Sommer Silke
The proteasome, a new target for cancer therapy
Gillessen Sommer S, Groettup M, Cerny T. The proteasome, a new target for cancer therapy. Onkologie 2002; 25:534-9.
Dec 1, 2002The proteasome, a new target for cancer therapy
Dec 1, 2002Onkologie 2002; 25:534-9
Gillessen Sommer Silke, Groettup M, Cerny Thomas
Mechanism of action of rituximab
Cerny T, Borisch B, Introna M, Johnson P, Rose A. Mechanism of action of rituximab. Anti-cancer drugs 2002; 13 Suppl 2:S3-10.
Nov 1, 2002Mechanism of action of rituximab
Nov 1, 2002Anti-cancer drugs 2002; 13 Suppl 2:S3-10
Cerny Thomas, Borisch Bettina, Introna Martino, Johnson Peter, Rose Andrea L
The war against nicotine and tobacco: new tools?
Cerny T. The war against nicotine and tobacco: new tools?. Onkologie 2002; 25:404.
Oct 1, 2002The war against nicotine and tobacco: new tools?
Oct 1, 2002Onkologie 2002; 25:404
Cerny Thomas
Preclinical development of a vaccine 'against smoking'
Cerny T, Lévy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, Patiny L, Tuchscherer G. Preclinical development of a vaccine 'against smoking'. Onkologie 2002; 25:406-11.
Oct 1, 2002Preclinical development of a vaccine 'against smoking'
Oct 1, 2002Onkologie 2002; 25:406-11
Cerny Thomas, Lévy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, Patiny L, Tuchscherer G
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
von Rohr A, Tobler A, Betticher D, Cerny T, Fey M, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9.
Oct 1, 2002Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
Oct 1, 2002Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9
von Rohr A, Tobler A, Betticher D, Cerny Thomas, Fey M F, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S-F H, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine
Pampallona S, Von Rohr E, Van Wegberg B, Bernhard J, Helwig S, Heusser P, Huerny C, Schaad R, Cerny T. Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie 2002; 25:165-70.
Apr 1, 2002Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine
Apr 1, 2002Onkologie 2002; 25:165-70
Pampallona S, Von Rohr E, Van Wegberg B, Bernhard J, Helwig S, Heusser P, Huerny C, Schaad R, Cerny Thomas
Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors
D'Addario G, Morant R, Boehme C, Cerny T. Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors. Onkologie 2002; 25:152-7.
Apr 1, 2002Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors
Apr 1, 2002Onkologie 2002; 25:152-7
D'Addario G, Morant R, Boehme C, Cerny Thomas
Advances in the treatment of non-Hodgkin's lymphoma
Cerny T, Gillessen Sommer S. Advances in the treatment of non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13 Suppl 4:211-6.
Jan 1, 2002Advances in the treatment of non-Hodgkin's lymphoma
Jan 1, 2002Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13 Suppl 4:211-6
Cerny Thomas, Gillessen Sommer Silke